Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis
Open Access
- 27 April 2023
- journal article
- research article
- Published by International Institute of Anticancer Research in In Vivo
- Vol. 37 (3) , 1037-1046
Abstract
Background/Aim: Non-alcoholic fatty liver disease is a major cause of liver-related morbidity and mortality. Metformin is a widely used medication and may have additional benefits beyond glycemic control. Liraglutide, a novel treatment for diabetes and obesity, also has beneficial effects on non-alcoholic steatohepatitis (NASH). Metformin and liraglutide have both benefited NASH treatment. However, no study has reported the effects of combination therapy with liraglutide and metformin on NASH. Materials and Methods: We investigated the in vivo effects of metformin and liraglutide on NASH in a methionine/choline-deficient (MCD) diet-fed C57BL/6JNarl mouse model. Serum triglyceride, alanine aminotransferase and alanine aminotransferase levels were documented. Histological analysis was performed according to the NASH activity grade. Results: After treatment with liraglutide and metformin, body weight loss improved, and the liver/body weight ratio decreased. The metabolic effects and liver injury improved. Liraglutide and metformin alleviated MCD-induced hepatic steatosis and injury. Histological analysis revealed that NASH activity was reduced. Conclusion: Our results provide evidence for the anti-NASH activity of liraglutide in combination with metformin. Liraglutide with metformin may offer the potential for a disease-modifying intervention for NASH.Keywords
This publication has 71 references indexed in Scilit:
- Metformin protects against ethanol-induced liver triglyceride accumulation by the LKB1/AMPK/ACC pathwayMolecular Biology Reports, 2022
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)Diabetologia, 2020
- Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivoBiochemical and Biophysical Research Communications, 2019
- Administration of methyl palmitate prevents non-alcoholic steatohepatitis (NASH) by induction of PPAR-αBiomedicine & Pharmacotherapy, 2019
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver DiseaseHepatology, 2019
- The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)Hormones, 2018
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysisClinics and Research in Hepatology and Gastroenterology, 2017
- Novel Pharmacotherapy Options for NASHDigestive Diseases and Sciences, 2016
- Comparative efficacy of anti‐diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized and non‐randomized studiesDiabetes/Metabolism Research and Reviews, 2015
- Metformin and metabolic diseases: a focus on hepatic aspectsFrontiers of Medicine, 2015